TW201722464A - 用於傷口癒合之纖維蛋白溶酶原給藥方案 - Google Patents

用於傷口癒合之纖維蛋白溶酶原給藥方案 Download PDF

Info

Publication number
TW201722464A
TW201722464A TW105136489A TW105136489A TW201722464A TW 201722464 A TW201722464 A TW 201722464A TW 105136489 A TW105136489 A TW 105136489A TW 105136489 A TW105136489 A TW 105136489A TW 201722464 A TW201722464 A TW 201722464A
Authority
TW
Taiwan
Prior art keywords
wound
plasminogen
biologically active
active variant
dose
Prior art date
Application number
TW105136489A
Other languages
English (en)
Chinese (zh)
Inventor
烏夫 貝特海姆
托爾 尼
皮爾瑞 拉瑞琳
馬丁 羅比泰利
Original Assignee
波麥堤克生化科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 波麥堤克生化科學有限公司 filed Critical 波麥堤克生化科學有限公司
Publication of TW201722464A publication Critical patent/TW201722464A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
TW105136489A 2015-11-10 2016-11-09 用於傷口癒合之纖維蛋白溶酶原給藥方案 TW201722464A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562253352P 2015-11-10 2015-11-10

Publications (1)

Publication Number Publication Date
TW201722464A true TW201722464A (zh) 2017-07-01

Family

ID=57485826

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105136489A TW201722464A (zh) 2015-11-10 2016-11-09 用於傷口癒合之纖維蛋白溶酶原給藥方案

Country Status (14)

Country Link
US (1) US20180326023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3373957A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018534306A (cg-RX-API-DMAC7.html)
KR (1) KR20180070708A (cg-RX-API-DMAC7.html)
CN (1) CN108289934A (cg-RX-API-DMAC7.html)
AU (1) AU2016352183A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009476A8 (cg-RX-API-DMAC7.html)
CA (1) CA3004509A1 (cg-RX-API-DMAC7.html)
IL (1) IL259172A (cg-RX-API-DMAC7.html)
MX (1) MX2018005876A (cg-RX-API-DMAC7.html)
RU (1) RU2018121234A (cg-RX-API-DMAC7.html)
TW (1) TW201722464A (cg-RX-API-DMAC7.html)
WO (1) WO2017081529A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803010B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN111432762B (zh) * 2017-12-15 2023-01-13 墨尼克医疗用品有限公司 预防性敷料
BR112020003022A2 (pt) 2017-12-26 2020-08-25 Hirotaro Fukuoka composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo
JP7682567B2 (ja) * 2020-11-17 2025-05-26 泰▲倫▼基国▲際▼有限公司 Ngfレベルを増加させる方法及び薬剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2249863A4 (en) * 2008-01-22 2011-12-28 Omnio Healer Ab METHOD OF ENHANCING WOUND HEALING
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法

Also Published As

Publication number Publication date
WO2017081529A1 (en) 2017-05-18
MX2018005876A (es) 2018-11-09
EP3373957A1 (en) 2018-09-19
RU2018121234A3 (cg-RX-API-DMAC7.html) 2020-03-12
AU2016352183A1 (en) 2018-06-28
CN108289934A (zh) 2018-07-17
KR20180070708A (ko) 2018-06-26
US20180326023A1 (en) 2018-11-15
ZA201803010B (en) 2019-07-31
IL259172A (en) 2018-06-28
JP2018534306A (ja) 2018-11-22
BR112018009476A8 (pt) 2019-02-26
RU2018121234A (ru) 2019-12-13
CA3004509A1 (en) 2017-05-18
BR112018009476A2 (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
Kalani et al. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers: long-term follow-up
Brem et al. Protocol for treatment of diabetic foot ulcers
Sankar et al. Evaluation of the efficacy of tranexamic acid on blood loss in orthognathic surgery. A prospective, randomized clinical study
Han et al. Topical and systemic anticoagulation in the treatment of absent or compromised venous outflow in replanted fingertips
Santagostino et al. Venous access in haemophilic children: choice and management
US20180326023A1 (en) Plasminogen dosage regimen for wound healing
Lowe et al. Double-blind controlled clinical trial of ancrod for ischemic rest pain of the leg
Deery II et al. Saving the diabetic foot with special reference to the patient with chronic renal failure
Lawrence et al. Ray amputation in a traumatic diabetic foot
Elkeles et al. ABC of vascular diseases. The diabetic foot
Edmonds A natural history and framework for managing diabetic foot ulcers
Mumcuoglu et al. The use of medicinal leeches in plastic surgery
Tió et al. Cost-effectiveness of post-operative cell salvage in total knee arthroplasty. Should we continue to recommend its use today?
Hon et al. Snakebite in a child: could we avoid the anaphylaxis or the fasciotomies?
Lin et al. Treatment and management after the replantation of amputated fingers
Ali et al. Outcome of partial nail plate and matrix removal (Winograd technique) for ingrown toe nail
Chen et al. Application of wound bed preparation theory in the management of a severe extravasation injury in a neonate: a case study
Mathew et al. Maxillofacial Trauma and Snake Bite-Incidence in Coincidence
Pavlovich et al. Injecting material for skin regeneration Lacerta application in treatment of trophic ulcers in patients with diabetic foot syndrome
Zulfa et al. Extravasation of 3% NaCl (Sodium Chloride) in Patients with Electrolyte Imbalance: A Case Report
Keshk et al. Reconstruction of complex soft tissue defects in the lower extremities with free anterolateral thigh perforator flap
Brown New treatments for lower extremity ulcers: Foot ulcers develop in approximately 15% of patients with diabetes. New therapeutic options include topical recombinant human growth factor and grafts of a human skin equivalent.(Foot ulcers)
Patel et al. Management of Non healing ulcer with local application of Yastimadhu Ghrita (Glycyrrhiza glabra L.)-A single case study
Brill et al. New therapeutic options for lower-extremity ulcers.
Bodegom et al. Surgical treatment of chronic osteomyelitis of the neuropathic toe